Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

5-Loxin is a natural remedy that successfully reduces joint pain and stiffness

Aug 06, 2012

The Boswellia serrata plant is also known as Indian frankincense. It has been used in traditional Indian medicine for centuries. Traditional Indian medicine is known as Ayurvedic medicine. Used for thousands of years, Ayurvedic medicine is the first system of healing based on strict scientific observation.

Boswellia supplies powerful natural ingredients known as Boswellic acids. The most potent of these is known as AKBA. A patent-pending blend of these Boswellic acids known as 5-Loxin improves joint comfort and mobility in patients with damaged knees or hips. This 5-Loxin is rich in AKBA and in fact 30% of it is comprised of AKBA. 5-Loxin is named for the nasty joint degrading enzyme that it inhibits which is known as 5-Lipoxygenase or 5-Lox.

Recently a ninety-day clinical trial was performed on seventy-five patients with arthritic knees (osteoarthritis of the knee). The patients received either 100mg of 5-Loxin, 250mg of 5-Loxin, or placebo daily for 90 days. At their first check up one week into the study there were already clinical improvements in pain score and functional ability in the group on the 250mg dosage. 5-Loxin was also as safe and side effect free as placebo. At the end of the ninety-day period both dosages of 5-Loxin conferred clinically and statistically significant improvements in knee pain and function. Additionally 5-Loxin significantly reduced the amount of the enzyme MMP3 (matrix metalloproteinase-3) in the synovial fluid of the knee.  MMP-3 is a collagen degrading enzyme that destroys the cartilage of the knee corroborating the decrease in knee pain with improvement in knee function and range of motion.

Patients on 5-Loxin had a reported improvement in quality of life, mobility and flexibility. Stiffness and pain were both dramatically improved with a 53% improvement in the WOMAC pain score, a 63% improvement in WOMAC stiffness score and a 50% improvement in WOMAC functional ability score. There was also a 66% improvement in VAS (Visual Analog Scale). VAS is the patients’ impression of disease severity and WOMAC is a score used by clinicians numbered from 1 to 100 evaluating the level of disease in a joint with 1 being healthy and 100 being a disaster. The study is published in the journal Arthritis Research and Therapy.